Phase 2 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any study procedures begin.
• Men or women of any race or ethnicity who are aged 40 or older and are expected to live at least one more year, in the opinion of the study doctor.
• People who weigh at least 45 kg (approximately 99 pounds).
• People who have been diagnosed with a lung condition called IPF (idiopathic pulmonary fibrosis) according to recognised international guidelines, with that diagnosis made no more than 8 years before joining the study, confirmed by a recent CT scan of the lungs taken within the last 6 months.
• People whose lungs are functioning at or above certain minimum levels on breathing tests at the time of screening (confirm specific thresholds with trial site).
• People whose lungs are able to transfer a sufficient amount of oxygen into the blood, as measured by a specific breathing test, at or above a minimum level at screening (confirm with trial site).
• People whose blood oxygen level while at rest is above 90%, measured by a small device clipped to the finger, while using no more than a low flow of supplemental oxygen through a nasal tube (confirm with trial site).

Who may not be able to join:

• People who have a documented diagnosis of coeliac disease.
• People who have had a lower respiratory tract infection (such as pneumonia or bronchitis) in the 4 weeks before screening, or who have had a recent sudden worsening of their IPF symptoms typically lasting less than one month.
• People who have been diagnosed with lung cancer, either currently or in the past.
• People whose lung CT scan shows a significant amount of a condition called emphysema (damage to air sacs in the lungs), where emphysema covers 20% or more of the lungs, or where emphysema appears more widespread than the scarring from IPF.
• People whose IPF is so advanced that a lung transplant is expected to be needed within 6 months of screening.
• People who have other serious and uncontrolled medical conditions — including other lung diseases, heart conditions, liver, kidney, digestive, hormonal, nerve, or mental health conditions — or active or untreated tuberculosis, that in the study doctor's opinion could affect participation.
• People who have any other lung condition (apart from IPF) that the study doctor believes may affect breathing test results.
• People who are currently taking, or have taken within the past 48 weeks, certain medicines that suppress or modify the immune system, or who have been taking steroid tablets (such as prednisone) at doses above 10 mg per day for more than 10 days.
• People who are known to be intolerant or allergic to any ingredient in the study treatment or other substances used in the study.
• People who have had a serious allergic reaction to certain types of antibody-based medicines (human, humanised, chimeric, or murine monoclonal antibodies) in the past.

Important: Always verify eligibility with the trial site directly before applying.